micardis and Dyrenium Interactions

Interactions between micardis(telmisartan) and Dyrenium (triamterene)

triamterene and telmisartan (Major Drug-Drug)

MONITOR CLOSELY: The concomitant use of potassium-sparing diuretics and angiotensin II receptor blockers (ARBs) may increase the risk of severe hyperkalemia. The mechanism is additive potassium-sparing effects. Both agents individually have been associated with hyperkalemia. Patients with diabetes, heart failure, dehydration, or renal insufficiency, or who are taking more than 25 mg/day of spironolactone may have a greater risk of developing severe hyperkalemia from this combination.

MANAGEMENT: Caution is advised if ARBs are used with potassium-sparing diuretics, particularly in patients with renal impairment, diabetes, old age, worsening heart failure, and/or a risk for dehydration. Serum potassium and renal function should be checked regularly, and potassium supplementation should generally be avoided unless it is closely monitored. Patients should be given dietary counseling and advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.